VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and PortfolioZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately. Christoph Erkel, previously Vice President of Research & Development at VERAXA, will apply his extensive management expertise in R&D to direct and accelerate development of the company’s proprietary BiTAC® (bi-targeted tumor-associated cytotoxicity) platform technologies, with the goal of developing safer and more effective cancer treatments for patients with solid tumors. He succeeds Rick Austin, Ph.D., who will be leaving the company after a successful transition period.
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development PlanScientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the development path for this novel therapeutic modality
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® PipelineArdigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)
VERAXA Biotech Appoints Rick Austin as Chief Scientific OfficerIndustry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies
